Coya Therapeutics Prices Upsized $20 Million Public Offering to Advance Treg-Based Therapies for Neurodegenerative Diseases Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company pioneering biologic therapies designed to enhance…
Emalex Biosciences’ Expanded Access Program for Investigational Tourette Syndrome Therapy Receives FDA Authorization Emalex Biosciences, a clinical-stage biopharmaceutical company focused on developing innovative treatments for neurodevelopmental and neurological disorders, today…
Orca Bio’s Orca-T Receives FDA Priority Review for Treatment of Blood Cancers, Marking Major Step Toward Potential First-in-Class Therapy Orca Bio, a late-stage biotechnology company pioneering high-precision cell therapies to…
Delta Dental of Tennessee Celebrates 60 Years with “60 Moments of Surprise Smiles” Campaign to Give Back to Communities Across the State Delta Dental of Tennessee (Delta Dental) is marking…
Aarvik Therapeutics Closes Series Seed 2 Financing Round, Accelerating Development of Next-Generation Cancer Therapies Aarvik Therapeutics, a pioneering biotechnology company specializing in antibody-drug conjugates (ADCs) and committed to advancing precision…
TAE Life Sciences’ Next-Generation Boron Drugs Show Promising Synergy with Immunotherapy in Preclinical BNCT Studies TAE Life Sciences (TLS), a leading biotechnology company focused on next-generation cancer therapies, today announced…
Versant Diagnostics Expands National Footprint with Strategic Partnership in Georgia, Strengthening Digital Pathology Access Versant Diagnostics (Versant), a pioneering independent physician services company specializing in digital anatomic pathology, has announced…
MindMed Study Highlights Alarmingly High Rates of Suicidal Ideation in Adults with Generalized Anxiety Disorder Researchers from Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), a late-stage clinical biopharmaceutical company pioneering innovative…
Candid Therapeutics Recognized as a 2025 Endpoints 11 Honoree, Highlighting Its Pioneering Work in T-Cell Engager Therapies Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company at the forefront of autoimmune…
ProteinQure Marks Milestone with First Patient Dosed in Phase I Clinical Trial of PQ203, a Computationally Designed Peptide Therapy for Advanced Metastatic Cancers ProteinQure, a Toronto-based biotechnology company at the…
Hallmark Health Care Solutions Appoints John Feminella as Senior Vice President of Data and Artificial Intelligence to Accelerate Workforce Transformation in Healthcare Hallmark Health Care Solutions (HHCS), a leading innovator…
Development of Combination Products: Critical Interactions Training Course to Address Regulatory, GMP, and CTD Requirements ResearchAndMarkets.com has announced the addition of the “Development of Combination Products: Critical Interactions Training Course”,…